ID18679A - USE OF FURTHER THERAPY - Google Patents

USE OF FURTHER THERAPY

Info

Publication number
ID18679A
ID18679A IDP971716A ID971716A ID18679A ID 18679 A ID18679 A ID 18679A ID P971716 A IDP971716 A ID P971716A ID 971716 A ID971716 A ID 971716A ID 18679 A ID18679 A ID 18679A
Authority
ID
Indonesia
Prior art keywords
further therapy
therapy
Prior art date
Application number
IDP971716A
Other languages
Indonesian (id)
Inventor
Annick Dr Vassout
Richard Katz
Debora Bennett
Lynn Dr Kramer
Kathleen Dr Hauser
Michael Dr Struck
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ID18679A publication Critical patent/ID18679A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4468Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
IDP971716A 1996-05-24 1997-05-23 USE OF FURTHER THERAPY ID18679A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1833696P 1996-05-24 1996-05-24

Publications (1)

Publication Number Publication Date
ID18679A true ID18679A (en) 1998-04-30

Family

ID=21787407

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP971716A ID18679A (en) 1996-05-24 1997-05-23 USE OF FURTHER THERAPY

Country Status (3)

Country Link
AU (1) AU2898297A (en)
ID (1) ID18679A (en)
WO (1) WO1997045119A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9716463D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
TW537894B (en) 1998-05-26 2003-06-21 Novartis Ag A spontaneously dispersible pharmaceutical composition comprising a piperidine substance P antagonist
GB9917408D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
GB9917406D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
WO2002008224A1 (en) 2000-07-26 2002-01-31 Smithkline Beecham P.L.C. Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
DE60210944T3 (en) 2001-02-23 2015-07-23 Merck Sharp & Dohme Corp. N-SUBSTITUTED NONARYL HETEROCYCLIC NMDA / NR2B ANTAGONISTS
CA2443108A1 (en) 2001-04-03 2002-10-17 Merck & Co. Inc. N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
AR038240A1 (en) 2002-01-29 2005-01-05 Glaxo Group Ltd PIPERIDINE COMPOUND, USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND PROCEDURE FOR PREPARATION
GB0220953D0 (en) * 2002-09-10 2002-10-23 Novartis Ag Organic compounds
US7592360B2 (en) 2003-06-04 2009-09-22 Merck & Co., Inc. 3-fluoro-piperidines as NMDA/NR2B antagonists
CN101065014A (en) * 2004-09-23 2007-10-31 亚历山大·米哈洛 Methods for regulating neurotransmitter systems by inducing counteradaptations
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
WO2007110449A1 (en) 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
TW200815353A (en) 2006-04-13 2008-04-01 Euro Celtique Sa Benzenesulfonamide compounds and their use
US8937181B2 (en) 2006-04-13 2015-01-20 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
KR101571522B1 (en) * 2014-04-09 2015-11-25 한국화학연구원 N--4-[b] - N-piperidin-4-ylbenzo[b]thiophenecarboxamide derivatives preparation method therof and pharmaceutical composition for use in preventing or treating Urotensin- receptor activity related diseases containing the same as an active ingredient
JP6706250B2 (en) 2015-04-20 2020-06-03 武田薬品工業株式会社 Heterocyclic compound
CA3041266A1 (en) 2016-10-18 2018-04-26 Takeda Pharmaceutical Company Limited Heterocyclic compound

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
GB9201179D0 (en) * 1992-01-21 1992-03-11 Glaxo Group Ltd Chemical compounds
TW397825B (en) * 1994-10-14 2000-07-11 Novartis Ag Aroyl-piperidine derivatives
WO1996024353A1 (en) * 1995-02-10 1996-08-15 Eli Lilly And Company Methods of treating or preventing psychiatric disorders
GB9505491D0 (en) * 1995-03-18 1995-05-03 Merck Sharp & Dohme Therapeutic agents
GB9505492D0 (en) * 1995-03-18 1995-05-03 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
AU2898297A (en) 1998-01-05
WO1997045119A1 (en) 1997-12-04

Similar Documents

Publication Publication Date Title
ID18679A (en) USE OF FURTHER THERAPY
NO992806D0 (en) Therapeutic agents
ID24118A (en) COMBINED THERAPY
DE69524193T2 (en) MASSAGER
ID24275A (en) COMBINATION THERAPY
DE69514764T2 (en) Massager
DE59710593D1 (en) therapy device
DE59711085D1 (en) therapy device
NO983090D0 (en) Therapeutic compounds
FI963263A0 (en) Medical use of bromelain
ID17383A (en) LATEST USE OF SISTINA DOWN
DE59710651D1 (en) sound therapy
KR970050954U (en) Physical Therapy Band
DE29602938U1 (en) Massager
MD281F1 (en) Magnetodynamic massage
MD940178A (en) Crutch
ID24439A (en) USE OF TIAZOLIDINDION FOR HYPERGLICEMIA TREATMENT
BR9604756A (en) Medical bathtub
ID24521A (en) USE OF TIAZOLIDINDION FOR HYPERGLICEMIA TREATMENT
KR950024525U (en) Acupuncture
SE9702595D0 (en) new therapeutic use
KR960009986U (en) Massager
DE29605685U1 (en) Therapy device
NO965332D0 (en) Therapeutic preparation
KR960004995U (en) Case of adjustable tissue